Niagen Bioscience, Inc. announced that its Board of Directors approved an increase in the share repurchase program authorization from $10.0 million to $20.0 million. The Company has repurchased approximately $2.6 million of common stock through March 17, 2026, to provide flexibility for returning capital to stockholders depending on market conditions.
Key takeaways
Board approved increase to $20.0 million share repurchase authorization from $10.0 million previously approved on October 31, 2025
Repurchased approximately $2.6 million of common stock through March 17, 2026
Program permits repurchases in open market, privately negotiated transactions, or via Rule 10b5-1 plan
Program effective through October 31, 2027 unless modified or terminated
CEO Rob Fried stated conviction in strategy and long-term value